TAB2 and metabolic dysfunction-associated steatohepatitis: Collectively, these data suggest TAB2 as a new target for TRIM38 in NASH and indicate that TRIM38 can interact with TAB2 and promoted its protein degradation, thus attenuating the activation of the MAPK signaling pathway.